Abstract 2459
Background
Arthralgia and myalgia are described with the vascular endothelial growth factor inhibitor Bevacizumab (Bev). However, in clinical practice these pains are not spontaneously reported by patients. We aimed to evaluate the frequency of arthralgia in patients treated by Bev and identify risk factors associated with arthralgia.
Methods
We conducted an observational, prospective, bicentric, health data study in two French centers. Self-administered questionnaires were distributed to patients at the initiation of Bev, at 3 months and at 6 months during treatment. We included patients treated for ovarian, colorectal or lung cancers. Bev (5 to 15 mg/kg) was administered intravenously every 2 or 3 weeks with chemotherapy most of the time.
Results
We included 71 patients from January 2018 to November 2018 (42 patients with colorectal cancer, 22 with ovarian cancer and 7 with lung cancer). Seventy-one patients completed the questionnaire at initiation, 56 (78,9%) at 3 months and 36 (50,7%) at 6 months. The frequency of joint pain before Bev initiation was 29,6% and increase at 3 months (41,8%, p = 0,18) and significantly at 6 months (50%, p = 0,04). The functional repercussion significantly increased for elementary activities from 5,9% at initiation to 12,7% at 3 months (p < 0,001) and to 16,7% at 6 months (p < 0,001). There was no difference for instrumental activities at 3 months (p = 0,07) and at 6 months (p = 0,07). In univariate analysis, the frequency of arthralgia increased significantly at 3 months for patients with Body Mass Index (BMI) > 25 kg/m2 (p = 0,04), ovarian cancer (p < 0,001), chemotherapy with Carboplatin (p = 0,01) and Paclitaxel (p < 0,001), 15 mg/kg dose of Bev (p < 0,001). At 6 months, women (p = 0,03), chemotherapy with carboplatin (p < 0,001) and paclitaxel (p < 0,001), 15 mg/kg dose of Bev (p < 0,001) were significantly associated with arthralgia occurrence. Nineteen patients (26,8%) wished to consult a rheumatologist.
Conclusions
Bevacizumab-associated protocols are responsible for a significant increase of arthralgia frequency in women treated for an ovarian cancer. The pain appears in the first 3 months and increase during treatment. Oncologists should be aware of this side effect in order to inform the patients and propose a suitable treatment.
Clinical trial identification
NCT03455907.
Editorial acknowledgement
Legal entity responsible for the study
Vieillard Marie-Hélène.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3181 - Effects of Three Products in the Prevention and Treatment of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
Presenter: Francesca Zannier
Session: Poster Display session 1
Resources:
Abstract
2433 - Boiling Histotripsy-induced Mechanical Ablation Modulates Tumour Microenvironment by Promoting Immunogenic Cell Death of Cancers
Presenter: Cheol-Hee Shin
Session: Poster Display session 1
Resources:
Abstract
2663 - The bacterial receptor NOD2 mediates LGR5+ intestinal stem cells protection against irradiation via mitophagy activation
Presenter: Antonin Levy
Session: Poster Display session 1
Resources:
Abstract
3213 - Pulse mode irradiation regimen of PDT results in high progression free and overall survival in mice with model tumor
Presenter: Alexey Bogdanov
Session: Poster Display session 1
Resources:
Abstract
3722 - Proton-sensitizing effect of small molecule inhibitor of P300 histone acetyltransferase C646 in human pancreatic cancer cells.
Presenter: Sungwon Shin
Session: Poster Display session 1
Resources:
Abstract
5805 - Red-Blood-Cell-Membrane-Enveloped Magnetic Nanoclusters as a Biomimetic Theranostic Nanoplatform for Bimodal Imaging Guided Cancer Photothermal Therapy
Presenter: sheng wang
Session: Poster Display session 1
Resources:
Abstract
5251 - Urine cell-free and extracellular vesicle cargo miRNAs as biomarkers for prostate cancer diagnosis
Presenter: Ivan Zaporozhchenko
Session: Poster Display session 1
Resources:
Abstract
3657 - Parkin, APEX1 and BCL2L1 Tissue Expression in Southern Brazilian Patients with Different Breast Cancer Molecular Subtypes
Presenter: Bianca Cabral
Session: Poster Display session 1
Resources:
Abstract
2839 - Obesity and prognosis in breast cancer
Presenter: Noha Ibrahim
Session: Poster Display session 1
Resources:
Abstract
5132 - SIPA1 is a modulator of HGF induced tumor metastasis via the regulation of tight junctions in lung adenocarcinoma cells
Presenter: Chang Liu
Session: Poster Display session 1
Resources:
Abstract